# A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

> **NCT01340846** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Warfarin
- **DRUG:** Ketoconazole
- **DRUG:** Gemfibrozil
- **DRUG:** GSK2118436 150mg
- **DRUG:** GSK2118436 75mg

## Key facts

- **NCT ID:** NCT01340846
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-03
- **Primary completion:** 2012-11-14
- **Final completion:** 2012-11-14
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340846, "A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01340846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*